A new experimental drug for spinal muscular atrophy from Roche subsidiary Genentech is showing promise, according to new data published Wednesday.
The new data shows that the drug, risdiplam, could help children with the debilitating illness sit up and move more easily. It’s an incremental new data set, but one that hints that the drug, if approved, could ultimately compete with Biogen’s pricey drug for the same condition, Spinraza. And the CEO of PTC Therapeutics, from which Genentech licensed the drug, is already hinting that the drug’s backers could file a new drug application with the FDA by the end of 2019.
About the Author Reprints
